The efficacy of vortioxetine on cognitive impairment in patients with major depressive disorder: a meta-analysis of randomized control trials
10.3760/cma.j.cn113661-20210516-00162
- VernacularTitle:伏硫西汀改善抑郁症患者认知功能障碍的Meta分析
- Author:
Xuxia MA
1
;
Yingying YUE
;
Yonggui YUAN
Author Information
1. 东南大学医学院，南京 210009
- Publication Type:Journal Article
- Keywords:
Depressive disorder;
Meta-analysis;
Cognition;
Vortioxetine
- From:
Chinese Journal of Psychiatry
2022;55(1):56-63
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy of votioxetine on the cognitive function in patients with major depressive disorder (MDD) by meta-analysis.Methods:PubMed, EMBASE, Cochrane Library, PsycINFO, web of science, CNKI and Wanfang databases were retrieved. The retrieval years were from the establishment of the database to July 9, 2021. Randomized controlled studies (RCTs) of votioxetine in the treatment of cognitive impairment in MDD patients were included for meta-analysis. The essential demographic characteristics, intervention programs, outcome indicators were extracted from the included literatures. Changes from baseline of cognition and function rating scales was chosen as primary outcome. The GRADE quality of evidence system was used to evaluate the quality of evidence. Meta-analysis was performed using Revman version 5.3.Results:Six RCTs were included in the current meta-analysis. Compared to patients in the placebo group, votioxetine statistically improved individual′s performance on the Rey Auditory Verbal Learning Test Acquisition (RAVLT Acquisition; SMD=0.19, 95% CI=0.06-0.33 , P=0.004 , I 2= 0%), Rey Auditory Verbal Learning Test Delayed Recall (RAVLT Delayed Recall; SMD=0.25, 95% CI=0.11-0.38, P=0.000 3, I 2= 0%), Trail Making Test A (TMT-A; SMD=-0.19, 95% CI=-0.32--0.06 , P=0.004 , I 2= 0%), Trail Making Test-B (TMT-B; SMD=-0.30, 95% CI=-0.43--0.17 , P<0.01, I 2= 0%) and Perceived Deficits Questionnaire-Depression (PDQ-D; SMD=-0.39, 95% CI=-0.52--0.27 , P<0.01, I 2= 0%) at the end of the 2nd and 8th weeks of treatment. Conclusion:Votioxetine has significant early efficacy in improving objective and subjective cognitive impairment in patients with MDD.
